David Zigdon is the CEO of Migvax, which is developing the MigVax-101 Covid-19 oral subunit vaccine for humans. He is a senior-level executive with a strong background in the High-Tech, Biomed, Biotech, and Pharma startup industry. Zigdon is also the CEO of the MIGAL Galilee Research Institute.
Prior to that, for approximately nine years, he was CEO and President of Rad BioMed, an Israel-based evergreen family fund that invests in early-stage BioMed startups. Rad BioMed is part of the RAD Group that has been named “the most fertile ground” for developing Israeli entrepreneurs.
Zigdon has also had a two-decade career as CEO/CFO of successful high-tech firms, including Bynet, Bynet Electronics, Radcom (Nasdaq: RDCM), Magic Software (Nasdaq: MGIC), and Time To Know. Zigdon is a CPA and holds a BA in Economics and an LLM from Bar Ilan University, Israel.
